Pancreatic Cancer (PaC) is the third leading cause of cancer-related death in western world. 80% of patients are unresectable at diagnosis and 40% of patients scheduled for surgery will not be resected eventually.
More biomarkers are needed to better stage patients.
The microRNA-99 family is an unfavorable prognostic factor in patients with pancreatic cancer (PaC). The aim of this study is to evaluate their value as biomarkers for resectability in PaC.
Preoperative blood samples from patients with PaC and tissue from either their specimen either their intraoperative biopsy will be harvested.
Expression of the microRNA-99 family, consisting of microRNA-99a, -99b, and -100, will be analyzed by qRT-PCR.
A multiparameter database with clinico-pathological and radiological features will be filled out.
The AUC of microRNA-99 family in predicting resectability will be tested in comparison with CA19.9 and clinical stage (cTNM).
Pancreatic Cancer (PaC) is the third leading cause of cancer-related death in western world. 80% of patients are unresectable at diagnosis and 40% of patients scheduled for surgery will not be resected eventually.
More biomarkers are needed to better stage patients.
The microRNA-99 family is an unfavorable prognostic factor in patients with pancreatic cancer (PaC). The aim of this study is to evaluate their value as biomarkers for resectability in PaC.